FIELD: medicine.
SUBSTANCE: invention refers to biotechnology. Offered application of sgk1 antibody is referred to as such providing change of sgk1 expression and/or function in eukaryotic cells, for diagnostics of diseases associated with inadequate activity of tissue factor. Discovered method concerns diagnostics of specified diseases and diagnostic set for detection of specified diseases based on antibody for diagnostics of diseases associated with inadequate activity of tissue factor. Invention application includes detection of tissue factor expression provided by change of sgk1, what can be applied in medicine for diagnostics of diseases associated with inadequate activity of tissue factor.
EFFECT: potential diagnostics of diseases associated with inadequate activity of tissue factor.
12 cl, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| KINASES sgk 2 AND sgk 3 AS THE TARGETS FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES | 2001 |
|
RU2310471C2 |
| QUANTITATIVE DIAGNOSTIC ANALYSIS OF HYPERTENSION | 2002 |
|
RU2287160C2 |
| DRUGS CONTAINING HUMAN h-sgk KINASE INHIBITORS CONTROLLING CELL VOLUME | 2000 |
|
RU2288718C9 |
| APPLICATION OF FVIIa OR TISSUE FACTOR ANTAGONIST TO REGULATE GENE EXPRESSION AND CELL JOURNEY OR CHEMOTAXIS | 2000 |
|
RU2268744C2 |
| NEW TISSUE FACTOR ANTIBODIES AS ANTICOAGULANTS | 2003 |
|
RU2345789C2 |
| COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | 2006 |
|
RU2383545C2 |
| MICROVESICLES DERIVED FROM RECOMBINANT YEAST HAVING HAEMOSTATIC ACTIVITIES AND USE THEREOF | 2007 |
|
RU2492184C2 |
| NEW THROMBOMODULINE FUSION PROTEINS PROVIDING DIRECTIONAL TRANSFER TO TISSUE FACTOR AS ANTICOAGULANTS | 2003 |
|
RU2320366C2 |
| COMPOUNDS AND COMPOSITIONS AS PROTEINKINASE INHIBITORS | 2006 |
|
RU2411242C2 |
| MODIFIED COAGULATION FACTOR VIIa WITH EXTENDED HALF-LIFE | 2007 |
|
RU2466141C2 |
